Previous 10 | Next 10 |
SAN DIEGO , Oct. 18, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will present new open-label extension data from the Phase 2 OASIS trial for its investigative drug candidate etrasimod, a next-generation, once-daily, oral, selective sphingosine 1-phosphate (S1P) ...
(Source - Pexels/Michael Fischer ) The Marijuana space is probably the single most interesting growth industry today. As the global trend has veered toward medical or even recreational legalization, the industry has shifted from the black market to the public markets. Thus far, public mar...
The major point for this article is to discuss the conflicting information that MannKind has issued in recent public events, information that is in direct conflict with information shared on every Afrezza prescription that is filled for a patient. The nature of this conflict is critical inform...
Arena Pharmaceuticals, Inc. (ARNA) 2019 Cantor Global Healthcare Conference October 02, 2019 03:00 PM ET Company Participants Amit Munshi - President & Chief Executive Officer Conference Call Participants Alethia Young - Cantor Fitzgerald Presentation Alethia Young ...
SAN DIEGO, Calif. , Sept. 26, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) presented new data from the Phase 2 OASIS trial for etrasimod, an investigational, once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor modulator, in development for a ran...
Arena Pharmaceuticals ( ARNA ) has taken a bit of a slide in recent weeks, and while there may be no immediate news on the horizon, the fundamentals that brought this stock as high as the mid $60s remain the same, if not improved. The stock is currently trading at about $48 per share, and the ...
SAN DIEGO , Sept. 25, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi , President and Chief Executive Officer of Arena, will present a corporate update at the Cantor Global Healthcare Conference on Wednesday, October 2 , at 3:0...
In early August, Rhythm Pharmaceuticals ( RYTM ) reported results from two phase 3 trials of its drug setmelanotide in rare genetic forms of obesity. The release of the results was met with a short term rally, but the stock found itself trading back at baseline within a few sessions. Throu...
SAN DIEGO , Sept. 17, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will present new preclinical data for etrasimod, an investigational, once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor modulator, in development for a range of immune-mediated a...
Healthcare development progress forecasts This article rewards investors who choose to direct their investments of TIME and capital to those securities with the highest likelihood of successful rates of return among alternatives compared under identical important measures. Readers famili...
News, Short Squeeze, Breakout and More Instantly...
Arena Pharmaceuticals Inc. Company Name:
ARNA Stock Symbol:
NASDAQ Market:
Arena Pharmaceuticals Inc. Website:
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded at a new 52-week high today of $99.95. So far today approximately 748,000 shares have been exchanged, as compared to an average 30-day volume of 1.2 million shares. Arena Pharmaceuticals is a biotechnology company targeting G-protein-couple...
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded today at a new 52-week high of $98.57. So far today approximately 748,000 shares have been exchanged, as compared to an average 30-day volume of 1.1 million shares. Over the past year, Arena Pharmaceuticals Inc. has traded in a range of $45...